(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF - 2NASA's giant moon rocket, in photos
- 3Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment
- 4With Obamacare premium hikes, more people opting for no coverage or cheaper plans
- 5Meet the astronauts about to make history on flight around the moon
- The 1 question we have to ask ourselves about the Taylor Frankie Paul 'Bachelorette' scandal
- 'Stranger Things' character guide: The nerds, the newcomers and the rest of the Season 5 cast
- I watched the buzzy new AI documentary — and left feeling both hopeful and terrified
- Rio Tinto resumes operations at three Pilbara port terminals after cyclone Narelle
- Artemis II shares new lunar images while more than halfway to the moon
- Air India chief resigns 10 months after devastating Ahmedabad crash and amid mounting financial troubles
- France bans Muslim gathering citing risk to participants
- Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
- Affordable Care Act enrollment is slightly ahead of last year, despite expiring subsidies
